entertainment -WSS

entertainment

author：leisure time 2025-10-04 03:59:30 - browse：136

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Change Healthcare outage fallout shows need for new oversight

focus

WSS

Pfizer plans to depart BIO

CMS should re

The woman behind the Dana Farber

Pfizer plans to depart BIO

Radiology is caught between AI's potential and concern for patients

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

leisure time

entertainment

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Male and female sex labels in research insufficient, scientists say

Continuity nursing helped my family in our darkest PICU moments

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Virginia high school admissions case could be legal follow

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Drug repurposing or repositioning? The language matters

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Americans' trust in science, scientist continues decline: Report

knowledge

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Radiology is caught between AI's potential and concern for patients

Pfizer plans to depart BIO

STAT letters to the editor on burnt

STAT letters to the editor on burnt

Pushing for an NIH office for post

hotspot

focus

explore

leisure time